Tate & Lyle and APC Microbiome Ireland announce publication of joint intellectual property on new synbiotic fibre product

The technology uses a new combination of a probiotic, Lactobacillus mucosae, and soluble dietary fibres which could lead to a number of positive metabolic health changes including in heart health, weight management, liver health, potentially improving immunity, lowering inflammation markers, and improving gut health.

The preliminary clinical research work on this jointly developed synbiotic ingredient, a combination of Tate & Lyle’s proprietary PROMITOR® fibre, and a proprietary shared by University College of Cork (UCC) and Teagasc Lactobacillus strain, has shown substantial and promising cardiometabolic health benefits. APC Principal Investigators Paul Ross, Catherine Stanton, Noel Caplice are co-inventors on the patent as well as project leads.

Tate & Lyle and APC Microbiome Ireland have an ongoing research partnership, which has recently been expanded and extended, looking into the metabolic pathways that could affect the relationship between the microbiome and health. It was this research partnership that led to this jointly filed patent application for this new ingredient technology.

Dr Kavita Karnik, Global Head, Nutrition & Regulatory Affairs at Tate & Lyle, said: “We are delighted, following our initial two-year research project with APC Microbiome, to have our joint patent application published for this ingredient technology that uses our PROMITOR® fibre. The health benefits this new synbiotic fibre ingredient could bring, such as improving heart health and tackling obesity, are exciting and another step on our journey to live our purpose of Transforming Lives through the Science of Food.

“As a science-driven organisation, we are pleased to be continuing our research with APC Microbiome Ireland, looking into the gut microbiome and the positive role fibres can play in improving our health.”

Prof Paul Ross, Director APC Microbiome Ireland, said: “This is an exciting announcement, and we are looking forward to continuing to work with Tate & Lyle to further uncover the health benefits of synbiotics.”

ENDS

Notes to editors

For media enquiries, please contact:

Shelley DeBere
Global External Corporate Comms Manager
Shelley.DeBere@tateandlyle.com
07584 540358

Tina Darb
APC Microbiome Ireland Communications Manager
tdarb@ucc.ie
00 353 87 7826500

Click here for our press image gallery

About Tate & Lyle: 
Tate & Lyle is a world leader in ingredient solutions for healthier food and beverages. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, mouthfeel and fortification, we develop solutions which reduce sugar, calories and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings.

We have more than 3,500 employees working in around 57 locations across 39 countries. Tate & Lyle's purpose is Transforming Lives Through the Science of Food and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2022, Tate & Lyle revenue from continuing operations totalled £1.4 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on Twitter, Linkedin or Facebook.